{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:13:54Z","timestamp":1793060034516,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.semarthrit.2015.11.012","type":"journal-article","created":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T12:46:46Z","timestamp":1449060406000},"page":"733-737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Tocilizumab in severe and refractory Behcet\u2019s disease: Four cases and literature review"],"prefix":"10.1016","volume":"45","author":[{"given":"Alban","family":"Deroux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chistophe","family":"Chiquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.11.012_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"Davatchi","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib2","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Behcet disease","volume":"67","author":"Davatchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","article-title":"Cytokine profile in Behcet\u2019s disease patients. Relationship with disease activity","volume":"31","author":"Hamzaoui","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0008-8749(92)90207-6","article-title":"Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet\u2019s disease","volume":"140","author":"Hirohata","year":"1992","journal-title":"Cell Immunol"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.mehy.2008.01.011","article-title":"Tocilizumab may be a potential addition to our weapons against neuro-Behcet\u2019s disease","volume":"71","author":"Haghighi","year":"2008","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","article-title":"A case of Behcet\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib7","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib9","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1167\/iovs.10-6272","article-title":"Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis","volume":"52","author":"Haruta","year":"2011","journal-title":"Invest Opthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/rheumatology\/keg453","article-title":"The Behcet\u2019s disease activity index","volume":"43","author":"Lawton","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib11","first-page":"509","article-title":"International Uveitis Study Group (IUSG) clinical classification of uveitis","volume":"140","author":"Deschenes","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","article-title":"Tocilizumab treatment for neuro-Behcet\u2019s disease, the first report","volume":"114","author":"Shapiro","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib13","first-page":"S73","article-title":"Refractory neuro-Beh\u00e7et treated by tocilizumab: a case report","volume":"30","author":"Urbaniak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/0886022X.2013.773913","article-title":"Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet\u2019s disease","volume":"35","author":"Redondo-Pach\u00f3n","year":"2013","journal-title":"Ren Fail"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib15","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","article-title":"Lack of efficacy of tocilizumab in mucocutaneous Behcet\u2019s syndrome: report of two cases","volume":"52","author":"Andreas","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12026-013-8411-1","article-title":"Refractory pemphigus foliaceus and Behcet\u2019s disease successfully treated with tocilizumab","volume":"56","author":"Caso","year":"2013","journal-title":"Immunol Res"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","article-title":"Tocilizumab for severe refractory neuro-Behcet: three case IL-6 blockage in neuro-Behcet","volume":"44","author":"Addimanda","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","article-title":"Paradoxical mucocutaneous flare in a case of Behcet\u2019s disease treated with tocilizumab","volume":"34","author":"Contarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib19","unstructured":"European Medicines Agency (EMEA). Assessment report for RoActemra. International Nonproprietary Name: Tocilizumab. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000955\/WC500111086.pdf\u3009; 2011 [accessed 08.07.14]."},{"key":"10.1016\/j.semarthrit.2015.11.012_bib20","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1546-0096-10-30","article-title":"Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome","volume":"10","author":"Kessler","year":"2012","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.11.012_bib22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/eci.10.70","article-title":"Tocilizumab for the treatment of rheumatoid arthritis","volume":"6","author":"Tanaka","year":"2010","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215002905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215002905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T07:24:31Z","timestamp":1537169071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215002905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0049017215002905"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.11.012","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab in severe and refractory Behcet\u2019s disease: Four cases and literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}